Open AccessM2 BPG i as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection
Author(s) -
Wei Bin,
Feng Shu,
Chen Enqiang,
Li Dongdong,
Wang Tingting,
Gou Yu,
Yang Tingting,
Zhang Dongmei,
Tao Chuanmin,
Tang Hong
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22261
Subject(s) - cirrhosis , gastroenterology , receiver operating characteristic , medicine , fibrosis , hepatitis b virus , liver fibrosis , stage (stratigraphy) , area under the curve , liver disease , hepatitis b , virus , immunology , biology , paleontology
Background M2 BPG i is a novel serum glycobiomarker of liver fibrosis. In this study, we aimed to evaluate the efficacy of M2 BPG i for predicting liver fibrosis and disease progression in Chinese hepatitis B virus ( HBV ) infected patients. Methods We enrolled 228 HBV infected patients with different status of liver fibrosis diagnosed using FibroScan. We analyzed the diagnostic accuracy of M2 BPG i, and compared it with AST ‐to‐platelet ratio ( APRI ), FIB ‐4 index, AST to ALT ratio ( AAR ), and RDW to platelet ratio ( RPR ). We performed receiver operating characteristics curve ( ROC ) to evaluate the diagnostic performance of M2 BPG i for significant fibrosis and cirrhosis. Results Median M2 BPG i values in each fibrosis stage were: 0.88 cut‐off index ( COI ) in F0‐1, 1.165 in F2‐3, and 1.92 in F4 ( P <.01), respectively. For F≥2, the sensitivity, specificity, accuracy of M2 BPG i were 72.28%, 73.23%, 66.67%, while 55.07%, 93.71%, 82.02% for F≥4. For predicting significant fibrosis (≥F2), M2 BPG i showed comparable performance to FIB 4 index ( P <.01), APRI ( P <.01) and RPR ( P <.01) with area under the ROC curve ( AUC ) of 0.788. M2 BPG i was superior to other surrogate markers for diagnosing cirrhosis (F4) with the highest AUC of 0.811 ( P <.01). Conclusions M2 BPG i levels increased with the progression of liver fibrosis in HBV infected patients. M2 BPG i can be served as a potential glycobiomarker to assess the stage of liver fibrosis, especially for the diagnosis of cirrhosis.